Detalhe da pesquisa
1.
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Blood
; 143(9): 786-795, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946283
2.
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Br J Haematol
; 184(2): 215-222, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30183069
3.
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.
Blood
; 130(26): 2829-2837, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29038340
4.
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 160(3): 321-30, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23150919
5.
Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local.
Hematology Am Soc Hematol Educ Program
; 2023(1): 311-317, 2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066909
6.
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 22(1): 52-59, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454850
7.
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Leuk Lymphoma
; 60(8): 1972-1977, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30633573
8.
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 18(8): e327-e331, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29934062
9.
WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY.
Retin Cases Brief Rep
; 11(2): 152-155, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27124793
10.
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
J Clin Oncol
; 27(30): 5023-30, 2009 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19770386